A top U.S. health official endorsed a key policy change on hormone replacement therapies while holding significant stock in a company that provides menopause treatments.

US Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In — ProPublica https://www.propublica.org/article/hhs-alicia-jackson-menopause-treatment-policy

Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In https://www.propublica.org/article/hhs-alicia-jackson-menopause-treatment-policy Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in a company providing access to menopause treatments. Ethics experts called her endorsement an “obvious conflict of interest.” --- 50 uses from 49 accounts #toplink

NEW: A top U.S. official endorsed a key policy change on hormone replacement therapies while holding at least $115,000 in stock in a company that provides access to menopause treatments. Ethics experts called it an “obvious conflict of interest.” https://www.propublica.org/article/hhs-alicia-jackson-menopause-treatment-policy?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post #News #Health #Women #Ethics #Conflict #Government #Business